In addition to PTCH1 mutation, a cohort of human tumor analysis revealed that medulloblastoma patients with p53 mutations have a much worse prognosis compared to those with wildtype p53 gene, strongly suggesting its involvement in tumor progression [18]. This evidence concerns the gene PTCH1 and medulloblastoma.